Ensysce Biosciences Inc Share Price Today: Live Updates & Key Insights

Ensysce Biosciences Inc share price today is $0.5516, up 1.58%. The stock opened at $0.5573 against the previous close of $0.575, with an intraday high of $0.5948 and low of $0.52975.

Ensysce Biosciences Inc Share Price Chart

Ensysce Biosciences Inc

us-stock
To Invest in {{usstockname}}
us-stock

Ensysce Biosciences Inc Share Price Performance

$0.5516 0.0158(1.58%) ENSC at 23 Mar 2026 12:53 PM Biotechnology
Lowest Today 0.52975
Highest Today 0.5948
Today’s Open 0.5573
Prev. Close 0.575
52 Week High 4.85
52 Week Low 0.31
Day’s Range: Low 0.52975 High 0.5948
52-Week Range: Low 0.31 High 4.85
1 day return -
1 Week return +35.96
1 month return +60.71
3 month return -51.11
6 month return -73.64
1 year return -83.32
3 year return -90.52
5 year return -99.98
10 year return -

Ensysce Biosciences Inc Institutional Holdings

Adage Capital Partners Gp LLC 4.12

Perceptive Advisors LLC 2.39

DRW Securities, LLC 1.90

Vanguard Group Inc 1.01

HRT FINANCIAL LLC 0.67

Financial Plan, INC. 0.66

Geode Capital Management, LLC 0.61

TWO SIGMA SECURITIES, LLC 0.59

Fidelity Extended Market Index 0.53

Williams & Novak LLC 0.49

Virtu Financial LLC 0.39

Vanguard Institutional Extnd Mkt Idx Tr 0.35

TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC 0.33

XTX Topco Ltd 0.30

Tower Research Capital LLC 0.15

Fidelity Series Total Market Index 0.05

Spartan Total Market Index Pool G 0.03

UBS Group AG 0.02

SBI Securities Co Ltd 0.01

BlackRock Inc 0.00

Bank of America Corp 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

Citadel Advisors Llc 0.00

Genworth Financial Wealth Mgmt Inc 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

Renaissance Technologies Corp 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Ensysce Biosciences Inc Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Ensysce Biosciences Inc Fundamentals

Market Cap 2.12 M

PB Ratio 1.7205

PE Ratio 0.0

Enterprise Value 0.84 M

Total Assets 5.60 M

Volume 586388

Ensysce Biosciences Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:2523380 2.5M, FY21:3531200 3.5M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:-1368841 -1.4M, FY19:-3328674 -3.3M

Annual Net worth FY23:-12599980 -12.6M, FY22:-24961561 -25.0M, FY21:-29145750 -29.1M, FY20:-938726 -0.9M, FY19:1476354 1.5M

Quarterly Revenue Q3/2025:493104 0.5M, Q2/2025:1371438 1.4M, Q1/2025:1320000 1.3M, Q3/2024:0 0.0M, Q2/2024:181797 0.2M

Quarterly Profit Q3/2025:-2461805 -2.5M, Q2/2025:-551992 -0.6M, Q1/2025:1320000 1.3M, Q3/2024:null 0.0M, Q2/2024:-765432 -0.8M

Quarterly Net worth Q3/2025:-3729128 -3.7M, Q2/2025:-1733351 -1.7M, Q1/2025:-1946000 -1.9M, Q3/2024:661769 0.7M, Q2/2024:-1967793 -2.0M

About Ensysce Biosciences Inc & investment objective

Company Information Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Organisation Biotechnology

Employees 7

Industry Biotechnology

CEO Dr. D. Lynn Kirkpatrick Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Ensysce Biosciences Inc FAQs

What is the share price of Ensysce Biosciences Inc today?

The current share price of Ensysce Biosciences Inc is $0.5516.

Can I buy Ensysce Biosciences Inc shares in India?

Yes, Indian investors can buy Ensysce Biosciences Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Ensysce Biosciences Inc shares in India?

You can easily invest in Ensysce Biosciences Inc shares from India by:

Can I buy fractional shares of Ensysce Biosciences Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Ensysce Biosciences Inc?

Ensysce Biosciences Inc has a market cap of $2.12 M.

In which sector does Ensysce Biosciences Inc belong?

Ensysce Biosciences Inc operates in the Biotechnology sector.

What documents are required to invest in Ensysce Biosciences Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Ensysce Biosciences Inc?

The PE ratio of Ensysce Biosciences Inc is N/A and the PB ratio is 1.72.